"Lymphocyte Count" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The number of LYMPHOCYTES per unit volume of BLOOD.
| Descriptor ID |
D018655
|
| MeSH Number(s) |
E01.370.225.500.195.107.595.500 E01.370.225.625.107.595.500 E05.200.500.195.107.595.500 E05.200.625.107.595.500 E05.242.195.107.595.500 G04.140.107.595.500 G09.188.105.595.500
|
| Concept/Terms |
Lymphocyte Count- Lymphocyte Count
- Lymphocyte Counts
- Lymphocyte Number
- Lymphocyte Numbers
- Total Lymphocyte Count
- Lymphocyte Count, Total
- Lymphocyte Counts, Total
- Total Lymphocyte Counts
|
Below are MeSH descriptors whose meaning is more general than "Lymphocyte Count".
Below are MeSH descriptors whose meaning is more specific than "Lymphocyte Count".
This graph shows the total number of publications written about "Lymphocyte Count" by people in this website by year, and whether "Lymphocyte Count" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2021 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lymphocyte Count" by people in Profiles.
-
Effector T cell responses unleashed by regulatory T cell ablation exacerbate oral squamous cell carcinoma. Cell Rep Med. 2021 09 21; 2(9):100399.
-
Dexamethasone suppresses immune evasion by inducing GR/STAT3 mediated downregulation of PD-L1 and IDO1 pathways. Oncogene. 2021 Aug; 40(31):5002-5012.
-
IRF4-dependent dendritic cells regulate CD8+ T-cell differentiation and memory responses in influenza infection. Mucosal Immunol. 2019 07; 12(4):1025-1037.
-
Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2018 06; 77(6):883-889.
-
Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. Arthritis Res Ther. 2015 Aug 20; 17:215.
-
Low total lymphocyte count is associated with poor survival in patients with resected pancreatic adenocarcinoma receiving a GM-CSF secreting pancreatic tumor vaccine. Ann Surg Oncol. 2013 Dec; 20 Suppl 3:S725-30.
-
Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia. Cancer. 2013 Jan 15; 119(2):363-70.
-
Tumor-associated antigen expressing Listeria monocytogenes induces effective primary and memory T-cell responses against hepatic colorectal cancer metastases. Ann Surg Oncol. 2012 Jul; 19 Suppl 3:S597-607.
-
Retinoids accelerate B lineage lymphoid differentiation. J Immunol. 2008 Jan 01; 180(1):138-45.
-
Cutting edge: Transitional T3 B cells do not give rise to mature B cells, have undergone selection, and are reduced in murine lupus. J Immunol. 2007 Jun 15; 178(12):7511-5.